Edition:
United States

Clovis Oncology Inc (CLVS.OQ)

CLVS.OQ on NASDAQ Stock Exchange Global Select Market

45.23USD
18 Jun 2018
Change (% chg)

$-0.33 (-0.72%)
Prev Close
$45.56
Open
$45.17
Day's High
$46.24
Day's Low
$44.37
Volume
372,635
Avg. Vol
406,056
52-wk High
$99.45
52-wk Low
$41.32

Chart for

About

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company's product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine... (more)

Overall

Beta: 1.34
Market Cap(Mil.): $2,394.13
Shares Outstanding(Mil.): 52.55
Dividend: --
Yield (%): --

Financials

  CLVS.OQ Industry Sector
P/E (TTM): -- 240.92 34.18
EPS (TTM): -4.45 -- --
ROI: -37.98 -5.87 13.17
ROE: -84.68 -7.71 15.15

BRIEF-Clovis Oncology Reports Q1 Loss Per Share $1.54

* CLOVIS ONCOLOGY ANNOUNCES FIRST QUARTER 2018 OPERATING RESULTS

May 08 2018

BRIEF-Clovis Oncology CEO Patrick Mahaffy's 2017 Total Compensation Was $8.7 Million

* CLOVIS ONCOLOGY INC SAYS CEO PATRICK MAHAFFY'S 2017 TOTAL COMPENSATION WAS $8.7 MILLION – SEC FILING Source text for Eikon: (http://bit.ly/2KnbE4y) Further company coverage:

Apr 27 2018

BRIEF-Clovis Oncology Announces Pricing Of Public Offerings Of Convertible Senior Notes And Common Stock

* CLOVIS ONCOLOGY ANNOUNCES PRICING OF PUBLIC OFFERINGS OF CONVERTIBLE SENIOR NOTES AND COMMON STOCK

Apr 16 2018

BRIEF-Clovis Oncology Files Prospectus Supplement Related To Offering $200 Mln Principal Amount Of Convertible Senior Notes

* CLOVIS ONCOLOGY INC FILES PROSPECTUS SUPPLEMENT RELATED TO OFFERING $200 MILLION PRINCIPAL AMOUNT OF CONVERTIBLE SENIOR NOTES DUE 2025 - SEC FILING Source text: (https://bit.ly/2qzin28) Further company coverage: (Reuters.Briefs@thomsonreuters.com)

Apr 16 2018

BRIEF-Clovis Oncology Files Prospectus Supplement Related To Offering $100 Mln Of Shares Of Co's Common Stock

* CLOVIS ONCOLOGY INC FILES PROSPECTUS SUPPLEMENT RELATED TO OFFERING $100 MILLION OF SHARES OF CO'S COMMON STOCK - SEC FILING Source text: (https://bit.ly/2HCYkbd) Further company coverage: (Reuters.Briefs@thomsonreuters.com)

Apr 16 2018

BRIEF-Clovis Oncology Says SEC Issued 'Wells Notices' To Co & Certain Of Its Officers

* CLOVIS ONCOLOGY SAYS ON APRIL 9 SEC ISSUED 'WELLS NOTICES' TO CO & CERTAIN OF ITS CURRENT AND FORMER OFFICERS - SEC FILING

Apr 10 2018

BRIEF-Clovis Oncology Says Rubraca Approved In U.S. As Maintenance Treatment Of Recurrent Ovarian Cancer

* RUBRACA (RUCAPARIB) APPROVED IN THE U.S. AS MAINTENANCE TREATMENT OF RECURRENT OVARIAN CANCER

Apr 06 2018

EMA panel for conditional OK to Clovis's ovarian cancer drug

A panel of European Medicines Agency (EMA) has recommended granting conditional marketing approval to Clovis Oncology's drug for ovarian cancer, citing anti-tumour activity.

Mar 23 2018

EMA panel for conditional OK to Clovis's ovarian cancer drug

March 23 A panel of European Medicines Agency (EMA) has recommended granting conditional marketing approval to Clovis Oncology's drug for ovarian cancer, citing anti-tumour activity.

Mar 23 2018

BRIEF-Clovis Oncology Initiates Early Access Program For Rucaparib

* CLOVIS ONCOLOGY INITIATES EARLY ACCESS PROGRAM FOR RUCAPARIB AS TREATMENT AND AS MAINTENANCE THERAPY IN RECURRENT OVARIAN CANCER IN EUROPE Source text for Eikon: Further company coverage:

Mar 23 2018

Competitors

Earnings vs. Estimates